These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12140809)

  • 1. Heart failure and Implantable Cardioverter Defibrillator (ICD) therapy: Update and perspective on current primary prevention trials.
    Saxon LA
    J Card Fail; 2002 Jun; 8(3):161-6. PubMed ID: 12140809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update of implantable cardioverter/defibrillator and cardiac resynchronization therapy in heart failure.
    Rami T; Shih HT
    Curr Opin Cardiol; 2004 May; 19(3):264-9. PubMed ID: 15096960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials.
    Wolff G; Lin Y; Karathanos A; Brockmeyer M; Wolters S; Nowak B; Fürnkranz A; Makimoto H; Kelm M; Schulze V
    Clin Res Cardiol; 2017 Jul; 106(7):501-513. PubMed ID: 28213711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Who should receive the subcutaneous implanted defibrillator?: The subcutaneous implantable cardioverter defibrillator (ICD) should be considered in all ICD patients who do not require pacing.
    Poole JE; Gold MR
    Circ Arrhythm Electrophysiol; 2013 Dec; 6(6):1236-44; discussion 1244-5. PubMed ID: 24347599
    [No Abstract]   [Full Text] [Related]  

  • 5. Primary prevention of sudden cardiac death: indications for cardioverter-defibrillator implantation.
    Botto GL; Proclemer A; Luzi M; Ruffa F; Gorgoglione MG; Ferrari G
    Ital Heart J; 2005 Mar; 6(3):210-5. PubMed ID: 15875511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardioverter-defibrillator does not improve short-term survival among patients with non-ischemic cardiomyopathy and reduced left ventricular ejection fraction.
    Jilek C; Lewalter T; Pauschinger M; von Scheidt W; Frankenstein L; Pfister O; Hambrecht R; Bruder O; Brachmann J; Hartmann A; Strasser R; Hochadel M; Senges J
    Clin Res Cardiol; 2020 Jan; 109(1):115-123. PubMed ID: 31236690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indications for ICD and cardiac resynchronization therapy for prevention of sudden cardiac death.
    Das M
    Expert Rev Cardiovasc Ther; 2009 Feb; 7(2):181-95. PubMed ID: 19210214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stimulation.
    Gatzoulis KA; Vouliotis AI; Tsiachris D; Salourou M; Archontakis S; Dilaveris P; Gialernios T; Arsenos P; Karystinos G; Sideris S; Kallikazaros I; Stefanadis C
    Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):504-12. PubMed ID: 23588627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New indications for implantable defibrillator therapy.
    Poole JE;
    Curr Cardiol Rep; 2006 Sep; 8(5):330-5. PubMed ID: 16956447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary prevention of sudden cardiac death by implantable cardioverter-defibrillator therapy in Chinese patients with heart failure: a single-center experience.
    Chen TB; Cheng KA; Gao P; Cheng ZW; Fan JB; Jiang XC; Fang Q
    Chin Med J (Engl); 2010 Apr; 123(7):848-51. PubMed ID: 20497676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and management of chronic heart failure with electrical therapy.
    Engelstein ED
    Am J Cardiol; 2003 May; 91(9A):62F-73F. PubMed ID: 12729852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biventricular pacing and defibrillator use in chronic heart failure.
    Cesario DA; Turner JW; Dec GW
    Cardiol Clin; 2007 Nov; 25(4):595-603; vii. PubMed ID: 18063163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
    Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
    Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
    BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
    Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study.
    Koller MT; Schaer B; Wolbers M; Sticherling C; Bucher HC; Osswald S
    Circulation; 2008 Apr; 117(15):1918-26. PubMed ID: 18391108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Inappropriate Shocks and Other Health Outcomes Between Single- and Dual-Chamber Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death: Results From the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter-Defibrillators.
    Peterson PN; Greenlee RT; Go AS; Magid DJ; Cassidy-Bushrow A; Garcia-Montilla R; Glenn KA; Gurwitz JH; Hammill SC; Hayes J; Kadish A; Reynolds K; Sharma P; Smith DH; Varosy PD; Vidaillet H; Zeng CX; Normand ST; Masoudi FA
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The assessment of factors influencing occurrence of adequate interventions of cardiac resynchronization therapy with cardioverter-defibrillator implanted in primary prevention of sudden cardiac death in dilative cardiomyopathy and percentage of biventricular pacing].
    Lelakowski J; Rydlewska A; Lelakowska M; Pudło J; Piekarz J; Matusik P
    Przegl Lek; 2017; 74(4):157-62. PubMed ID: 29696953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study.
    Duncker D; König T; Hohmann S; Bauersachs J; Veltmann C
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.